Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
The European Respiratory Journal|December 3, 2008
Differential diagnosis and management of focal ground-glass opacitiesM Infante, R F Lutman, S Imparato, et al.
Tumori|January 24, 2026
Medical decision analysis for personalized oncology at the patient bedsideP G Casali, L Licitra, S Provenzano, et al.
CNS Drugs|June 28, 2018
Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?Chiara Zecca, G Bellavia, L Brambilla, et al.
Journal of Neurology|June 28, 2018
Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre studyGiulia Mallucci, P Annovazzi, S Miante, et al.
ESMO Open|February 2, 2023
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
International Journal of Cancer|September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical researchF Pietrantonio, M Caporale, F Morano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinomaG Rosati, G Ambrosini, S Barni, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health recordsL Mazzeo, F Corso, P Baili, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Pageof 11